Tagged with Sanofi

Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…

CSR The President & CEO of Sanofi Canada talks candidly about the pros and cons of the current administrative setup of the Canadian healthcare sector; Concerto, an association in Quebec that puts innovative pharma alongside government and regulators, and the local implications of the global trend of diversification in Big Pharma.…

Generics Eric Ng received his degree at National University of Singapore. In his career he has worked for such companies as AstraZeneca before moving to Sanofi-Aventis China until his rise in rank to President Director of Sanofi in Indonesia. Today he talks about the stiff competition in Indonesia in the generics…

Sanofi Ireland Ms. Dickens, in our interview with your Sanofi colleague Jan Hendrix in Belgium last month, he commented that it is amazing how diversified this company has become in just the last four years. From your own perspective, how has the company developed over this period, and why do you believe…

Sanofi China Among Big Pharma, Sanofi has a track record of placing a lot of faith in emerging markets – with local production, a large product portfolio, and decades of experience. As the largest and fastest-growing emerging market, what is the strategic importance of China to Sanofi? And, vice versa, where does…

Sanofi - Belgium Mr Hendrickx, considering that you have been with Sanofi for over a decade, what would you describe as the single most important change in Sanofi’s business model? In essence, it is the diversification of Sanofi into a wide range of business activities. In the past, Sanofi was very successful at…

Sanofi-Aventis Philippines Mr. Realuyo, you have been in sanofi-aventis for 16 years, three of which were at the head. What have been the major achievements that the company has reached since your appointment as President & General Manager? In the last years, the pharmaceutical industry has been able to engage with the…

Sanofi Mexico Sanofi acquired Kendrick in 2009. Obviously the thinking behind it was to diversify your products into pure generics, but what were the expectations for the move? We have a diversified strategy focused on patient´s needs. As a leader in the industry, we changed the way we see and understand healthcare.…

Sanofi Pasteur Thailand You moved from the post of President for Sanofi Pasteur in Korea to President of Sanofi Pasteur in Thailand 1,5 years back. What have been the milestones so far and what have been the most important lessons learnt? Thailand is a country of dynamism. Thai people are very professional and…

Sanofi Australia What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas of cardiometabolic disease, thrombosis, oncology, vaccines, CNS, and internal medicine. The PBS reforms clearly are the major reforms over the…

Sanofi Ukraine What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies have an LLC now, for two key reasons. Firstly, it is risky to become too big and visible while continuing…

Sanofi SA Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The healthcare market has seen a major shift in the way the pharmaceutical sector and the South African government engage with…